Presenting a pragmatic model for evaluating the economic performance of hospitals in Iran based on multi-criteria decision-making [0.03%]
基于多准则决策的伊朗医院经济绩效评估模型研究
Jalal Saeidpour,Ehsan Teymourzadeh,Parisa Mehdizadeh et al.
Jalal Saeidpour et al.
Background: Evaluating the economic performance of hospitals is crucial for improving efficiency and aligning healthcare services with organizational missions. This study presents an operational model for assessing the ec...
Provider behavior from FFS to DRGs payment: experimental evidence from real physicians [0.03%]
来自真实医生的实证证据：从按服务付费到按病种付费中的供应商行为变化
Yefeng Chen,Weizheng Zhao,Ying Liu et al.
Yefeng Chen et al.
Background: Controlling the escalation of healthcare costs is a critical issue in China, which has led to a shift in the health insurance payment system from Fee-for-Service (FFS) to Diagnosis-Related Groups (DRGs). While...
Cost-effectiveness analysis of intensive and emerging rehabilitation therapies in children with cerebral palsy: an observational cohort study using real-world evidence and microsimulation modelling [0.03%]
基于真实世界证据和微模拟建模的儿童脑瘫密集型及新兴康复疗法的成本效益分析：观察性队列研究
Diana Marcela Nova-Díaz,Sergio Aguilera-Albesa,Eduardo Sánchez-Iriso
Diana Marcela Nova-Díaz
Objective: To evaluate the short- and long-term cost-effectiveness of integrating Intensive and Emerging Rehabilitation Therapies into standard care for children with cerebral palsy (CP), compared to standard care alone, ...
Has volume-based procurement reduced household catastrophic health expenditure in rural patients with chronic disease?-Evidence from CHARLS 2018 and 2020 in China [0.03%]
基于量的采购能否减轻中国农村慢性病患者的健康灾难性支出？来至CHARLS 2018和2020年的证据
Shaoliang Tang,Shuo Sun,Yunjie Feng et al.
Shaoliang Tang et al.
Background: The volume-based procurement aims to reduce drug prices, alleviate the burden of medical costs on residents, and improve public health and well-being. ...
Economic burden of blindness and moderate to severe vision impairment in Slovenia [0.03%]
斯洛文尼亚盲人和中重度视力损害的经济负担
Nina Vidic Krhlikar,Dalibor Gavrić,Mojca Globočnik Petrovič et al.
Nina Vidic Krhlikar et al.
Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis [0.03%]
帕博利珠单抗联合卡铂-紫杉醇一线治疗pPSR患者的成本效益：分区生存分析
Ziyad S Almalki,Saba S Albanna,Yahia A Hadadi et al.
Ziyad S Almalki et al.
Costs and cost-effectiveness of type 2 diabetes management in Sub-Saharan Africa: a systematic review [0.03%]
非洲撒哈拉以南地区2型糖尿病管理的成本和成本效益：系统评价
Assegid Hellebo,Andre P Kengne,Olufunke A Alaba
Assegid Hellebo
The economic burden of COVID-19 undervaccination: costs of hospitalisation, ICU admission, and death in Scotland [0.03%]
Covid-19低接种率带来的经济负担：苏格兰住院、重症监护和死亡的费用
Steven Kerr,Joan E Madia,Catia Nicodemo et al.
Steven Kerr et al.
Consideration of the limitations of cost-effectiveness analysis for severe-rare disease drugs and potential solutions: a structured literature review [0.03%]
成本效益分析在罕见病和严重疾病的局限性及潜在解决方案的结构化文献回顾
Jia Pan,Anastasios Skroumpelos,Anouska Jha et al.
Jia Pan et al.
Background: Rare diseases affect more than 400 million people globally with only a small number having currently approved treatments. Drugs for rare diseases (medications developed to treat conditions affecting small pati...
Economic evaluation of automated scalp cooling systems for breast cancer patients in Spain [0.03%]
西班牙乳腺癌患者自动头皮冷却系统经济评估研究
Hernández-Yumar Aránzazu,García-Pérez Lidia,González-Pacheco Himar et al.
Hernández-Yumar Aránzazu et al.